Form
SCHEDULE 13G/A
Passive or exempt beneficial ownership filing.
Sofinnova Partners SAS - 31 Mar 2025 SCHEDULE 13G/A Report for Quince Therapeutics, Inc. Common Stock, par value $0.001 per share (QNCX)
- Filing manager
- Sofinnova Partners SAS
- Reporting owner
- Sofinnova Capital VIII
- Beneficially owned shares
- 1,197,711 shares
- Large-stake signal
-
Ownership
2.7%Beneficial ownership of this reported class.
Shares
1,197,711 sharesShares beneficially owned as disclosed.
Event date
31 Mar 2025Date tied to the ownership event or amendment.
Accepted by SEC
30 Apr 2025EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 2.7%
- Symbol
- QNCX
- Shares outstanding
- 44,359,667 shares
- SEC form
- SCHEDULE 13G/A
- Accepted by SEC
- 30 Apr 2025, 16:06:36 UTC
- Event date
- 31 Mar 2025
- Prior SEC filing
- 14 Feb 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
5 source fields
Key filing fact
Sofinnova Partners SAS disclosed 2.7% ownership in Quince Therapeutics, Inc. Common Stock, par value $0.001 per share (QNCX) on 31 Mar 2025.
Key facts
- Sofinnova Partners SAS filed SCHEDULE 13G/A for Quince Therapeutics, Inc. Common Stock, par value $0.001 per share (QNCX).
- Disclosed ownership: 2.7%.
- Date of event: 31 Mar 2025.
Change
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 30 Apr 2025, 16:06.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (8)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Sofinnova Capital VIII | 2.7% | 1,197,711 | 1,197,711 | 0 | /s/ Antoine Papiernik | Antoine Papiernik / Managing Partner | |
| Sofinnova Partners SAS, a French Corporation | 2.7% | 1,197,711 | 1,197,711 | 0 | /s/ Antoine Papiernik | Antoine Papiernik / Managing Partner | |
| Antoine Papiernik | 2.7% | 1,197,711 | 1,197,711 | 0 | /s/ Antoine Papiernik | Antoine Papiernik | |
| Henrijette Richter | 2.7% | 1,197,711 | 1,197,711 | 0 | /s/ Henrijette Richter | Henrijette Richter | |
| Maina Bhaman | 2.7% | 1,197,711 | 1,197,711 | 0 | /s/ Maina Bhaman | Maina Bhaman | |
| Graziano Seghezzi | 2.7% | 1,197,711 | 1,197,711 | 0 | /s/ Graziano Seghezzi | Graziano Seghezzi | |
| Anta Gkelou | 2.7% | 1,197,711 | 1,197,711 | 0 | /s/ Anta Gkelou | Anta Gkelou | |
| Karl Naegler | 2.7% | 1,197,711 | 1,197,711 | 0 | /s/ Karl Naegler | Karl Naegler |
CIK / CUSIP context first